Account
Newsletter
15.03.2023
PMA Insights: Week 11

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Articles
07.03.2023
Are acute therapies and curative drugs more afford...

We've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...

Read more
Newsletter
02.02.2023
PMA Insights: Week 5

We summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...

Read more
Newsletter
16.11.2022
PMA Insights: Week 46 SPECIAL EDITION ISPOR 2022 R...

We summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...

Read more
Publications
19.10.2022
ISPOR 2022: Changing landscape of Orphan Drug Reim...

We compare the rates of positive reimbursement decisions in England and EU4 for orphan drugs approve...

Read more
Insider Insights
11.07.2022
New pharmaceutical updated cost containment measur

This updated bill contains some similar measures to those proposed in March as well as some addition...

Read more
Insider Insights
29.04.2022
EUCOPE anticipates OMP Regulation review

EUCOPE notes that “while these proposals don’t necessarily represent the final options included ...

Read more
Insider Insights
21.04.2022
Innovation and affordability of orphan drugs

The paper examines potential reforms to current policies and practices related to orphan drug develo...

Read more
Insider Insights
14.04.2022
Latest survey shows disparities in access

The study, compiled by IQVIA, covers 160 drugs, including 41 oncology drugs and 57 orphan drugs whic...

Read more
Insider Insights
11.04.2022
Streamline negotiation of price conditions

The amendment includes a number of articles which aims to “streamline the negotiation of the price...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.